ARMP — Armata Pharmaceuticals, Inc.

—
NYSE · Health Care · Biotechnology · CIK 921114 ·
Last close
$3.78
Market Cap
$140.55M
52W High
$16.34
52W Low
$2.94
ADV30
283,300
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 — — — — — — —
Mar 2026 0 — -8,785,000 -115,346,000 69,800,000 4,754,000 381,386,000
Dec 2025 0 — -8,411,000 -124,298,000 76,882,000 8,688,000 295,478,000
Sep 2025 0 — -7,776,000 -26,675,000 89,516,000 14,756,000 185,104,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-23,965,000
Investing CF
$-506,000
Financing CF
$16,267,000
CapEx
$-506,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.55
As of
2026-08-16

Balance + Analyst (yfinance extras)

Retained Earnings
$-616,880,000
Inventory
—
Receivables
$47,000
ST Investments
—
EBIT TTM
$-264,067,000
Pretax Income TTM
$-282,614,000
Interest Exp TTM
$18,547,000
Analysts
2

Yahoo Snapshot (yfinance, live)

Total Revenue
$5,543,000
EBITDA
$-33,448,000
Free Cash Flow
$-27,409,624
Enterprise Value
$490,040,032
Total Cash
$23,952,000
Total Debt
$313,952,992
Shares Out
37,181,979
Trailing EPS
$-5.29
Book Value
$-6.22
ROE
—
ROA
-25.8%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -31,222,000 -173,799,000 76,882,000 295,478,000 -218,596,000 -25,763,000
Dec 2024 0 -42,436,000 -18,916,000 86,437,000 134,456,000 -48,019,000 -37,551,000
Dec 2023 0 -40,890,000 -69,045,000 98,363,000 130,428,000 -32,065,000 -47,423,000
Dec 2022 0 -36,946,000 -36,917,000 95,834,000 59,754,000 36,080,000 -32,481,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.57

Peers — same industry

TickerNameMarket CapLastDaily %
MOLN MOLECULAR PARTNERS AG $147.86M $3.86 —
TNYA Tenaya Therapeutics, Inc. $132.25M $0.59 —
ENGN enGene Therapeutics Inc. $132.02M $1.97 —
CRBU Caribou Biosciences, Inc. $131.87M $1.23 —
OTLK Outlook Therapeutics, Inc. $151.21M $0.62 —

News headlines (Yahoo Finance, 1h cache)

Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development
2026-09-23 11:00 · Yahoo
Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates
2026-09-21 11:00 · Yahoo
Armata Pharmaceuticals Shares Rise 8% After FDA Grants AP-SA02 Breakthrough Therapy Designation
2026-09-14 13:34 · Yahoo
Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02
2026-09-14 11:00 · Yahoo
Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-10 11:00 · Yahoo
Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials
2026-09-03 11:00 · Yahoo
Armata Pharmaceuticals (ARMP) Stock Jumps 12.2%: Will It Continue to Soar?
2026-07-21 11:05 · Yahoo
Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02
2026-07-20 11:00 · Yahoo
Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphylococcus aureus Bacteremia
2026-07-13 11:00 · Yahoo
Armata Pharmaceuticals Receives $2.5 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support AP-SA02
2026-06-23 11:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.